What are the differences between inclisiran and evolocumab regarding mechanism of action, dosing schedule, efficacy, safety, and cardiovascular outcome evidence?

Evolocumab is Preferred Over Inclisiran as First-Line PCSK9 Inhibitor Therapy

Evolocumab should be your first choice for PCSK9 inhibition due to proven cardiovascular outcomes benefits, while inclisiran is reserved for patients with demonstrated poor adherence to monoclonal antibodies or those unable to self-inject. 1

Key Differences Between the Agents

Mechanism of Action

• Evolocumab: Human monoclonal antibody (IgG2) that binds circulating PCSK9 protein, preventing it from degrading LDL receptors on hepatocytes 1, 2
• Inclisiran: Small interfering RNA (siRNA) that targets PCSK9 messenger RNA in hepatocytes, reducing PCSK9 synthesis at the genetic level 3

Both mechanisms ultimately increase LDL receptor availability and lower LDL-C, but through fundamentally different pathways—one blocks the protein, the other silences its production.

Dosing Schedule: A Critical Practical Difference

Evolocumab:

• 140 mg subcutaneously every 2 weeks OR 420 mg monthly 1, 2
• Requires 12-26 injections annually
• Refrigeration required

Inclisiran:

• 284 mg subcutaneously at Day 1, Day 90, then every 6 months 3
• Only 3 injections in year one, 2 injections annually thereafter
• This twice-yearly dosing is inclisiran's primary advantage

LDL-C Lowering Efficacy: Essentially Equivalent

Both agents achieve robust LDL-C reductions of approximately 50-60% when added to maximally tolerated statin therapy 1. Real-world data confirms no significant differences in LDL-C lowering between the agents at 3 and 15 months 4, 5.

Important nuance: Inclisiran showed a numerical (though not statistically significant) advantage in apolipoprotein B reduction in one real-world study (0.650 g/L vs 0.774 g/L for evolocumab) 5, which may have clinical relevance given apoB's role as a superior marker of atherogenic particle burden.

Both agents reduce Lp(a) by approximately 25%, with no significant differences between them 6.

Cardiovascular Outcomes: The Decisive Factor

This is where the evidence diverges critically:

• Evolocumab: Proven reduction in cardiovascular death, MI, stroke, and coronary revascularization in the FOURIER trial 1
• Inclisiran: No completed cardiovascular outcomes trials. ORION-4 and VICTORION-2P are ongoing, with completion anticipated in 2026-2027 1

The 2022 ACC Expert Consensus explicitly states that PCSK9 monoclonal antibodies are preferred as the initial PCSK9 inhibitor of choice based on demonstrated safety, efficacy, and cardiovascular outcomes benefits. 1

Safety Profile

Both agents demonstrate favorable safety profiles with no new concerning signals 4, 5.

Evolocumab: Most common adverse effects include nasopharyngitis, injection site reactions, and upper respiratory infections 1

Inclisiran: Post-marketing surveillance identified musculoskeletal disorders and injection site reactions as most common, with median AE onset at 43 days 7. No evidence of increased cognitive adverse effects with either agent.

Clinical Decision Algorithm

Choose Evolocumab (or Alirocumab) When:

• Initiating PCSK9 inhibitor therapy in any patient
• Patient has established ASCVD requiring proven outcomes benefit
• Patient can manage every-2-week or monthly injections
• Rapid titration or dose adjustment may be needed

Consider Inclisiran Instead When:

• Documented poor adherence to PCSK9 monoclonal antibodies (this is the primary indication) 1
• Adverse effects from both evolocumab AND alirocumab
• Patient unable to self-inject and requires healthcare provider administration (twice-yearly visits more feasible)
• Patient strongly prefers less frequent dosing

Critical Caveats

Never combine inclisiran with PCSK9 monoclonal antibodies—there is no evidence or mechanistic plausibility for additional benefit, and inclisiran should only be used in place of, not in addition to, monoclonal antibodies 1.

Patients with heterozygous familial hypercholesterolemia may require closer monitoring when switching from evolocumab to inclisiran, as 25% exceeded LDL-C targets in one real-world study 8. Treatment persistence was actually higher with inclisiran (69.7%) versus evolocumab (56.1%) in real-world data 5, supporting its use in adherence-challenged populations.

Cost considerations: While not addressed in clinical guidelines, the less frequent dosing of inclisiran may reduce healthcare utilization costs despite similar drug acquisition costs, particularly relevant for patients requiring provider-administered injections.

The evidence hierarchy is clear: prioritize proven cardiovascular benefit (evolocumab) unless specific patient factors—primarily adherence issues—make inclisiran's dosing schedule a compelling alternative. 1